T-cell factor 4 (TCF-4) is determined to play a crucial role in Wnt/b-catenin signaling pathway activation. The mutations and alternative splice isoforms of TCF-4 can cause cancers and other diseases. The high-mobility group (HMG) box domain of TCF-4 contributes to interacting with DNA motif for transcriptional regulation. However, the impact of the mutations within HMG box of TCF-4 on the genomic binding pattern is poorly investigated. Herein, we generated nonesmall cell lung cancer (NSCLC) cell line A549 with stably overexpressed TCF-4 with HMG box hot spot mutation (10th exon partial deletion), and conducted TCF-4 and b-catenin chromatin immunoprecipitation sequence to explore the differential genomic binding patterns. Our results revealed that TCF-4 lost 19365 but gained 1724 peaks, and b-catenin lost 4035 but gained 5287 peaks upon mutant TCF-4 compared with the wild type (log2FC > 1 or < -1, FDR<0.01). The transcriptional levels of the genes associated with these differential peaks such as H3F3C, KRT1, KRT14, MMp1, and MMP15 were all found to strongly change responding to TCF-4 binding (P < 0.05). Furthermore, A549 cells with TCF-4 mutation displayed a more compromising tumor characterization on cell proliferation and invasion. Our data determined the important role of TCF-4 in gene transcription controlling and provided the gain function evidence of TCF-4 caused by the TCF-4 mutation in NSCLC.
Background T-cell factor 4 (TCF-4) is a member of the TCF/lymphoid enhancer factor (LEF) family, which can recognize a consensus motif of Ephrussi-box binding site in the promoter region [1] . TCF-4 together with b-catenin coactivator, functions as the major transcriptional mediator of the canonical wingless/integrated (Wnt) signaling pathway, which is one of the pivotal mechanisms involved in the progression of the multiple cancers [2e4]. Usually, TCF-4 is extensively expressed in various cancers and is closely correlated with cancer progression, and silencing the aberrant expression of TCF-4 can efficiently repress the tumor cell growth and proliferation [5] , which indicates that TCF-4 plays an oncogenic role and can be served as a potential therapeutic target for cancer treatment. Previous studies revealed that TCF-4 was causally connected with the development of lung carcinoma [6] by regulating multiple downstream genes, such as MMP15 [7] , RUNX3, TMEM88, and APC [8] .
TCF-4 consists of three major domains including 1st exon for the b-cateninebinding domain, 10th and 11th exons for the DNA-binding high-mobility group (HMG) boxes, and the 17th exon for C-terminal binding domain [6] . The b-cateninebinding domain contributes to the interaction with b-catenin to form the complex and activate the transcription of target genes. C-terminal binding domain produces a variety of TCF-4 splicing isoforms in different types of cancers [9] , which strongly affects the tumor malignancy and patients survival status [10] . HMG box plays a crucial role in DNA motif recognition and binding. As a DNA-binding protein, TCF-4 acts as an independent transcriptional regulator unless TCF-4 recruits other transcriptional factors to activate gene transcription. One study reported that exon 11 played a crucial role in binding activity on the canonical binding site in lung cancer [6] , and the entire loss of exon 11 caused the transcriptional suppression of Wnt signaling targets, and could mimic the antitumor effect of Wnt signaling inhibitor. However, how the mutations of HMG box impact on the DNA motif preference and genomic DNA binding still remain obscure. In this study, we generated the HMG box mutation of TCF-4 and investigated the genomic binding pattern of TCF-4 and b-catenin in nonesmall cell lung cancer (NSCLC) cells. Our study tried to reveal the function loss and gain of TCF-4 derived from the DNA-binding domain mutation and illustrated the carcinogenic mechanism of Wnt/b-catenin signaling pathway.
Methods

TCGA Data Mining
TCGA PanCancer Atlas studies with 32 types of cancer (10528 cases samples) [11] were picked out to investigate TCF-4 mutations and compare the relationship with tumor malignancy. The data were output from cBioPortal (https://www.cbioportal.org/) [12, 13] .
Cell Line Preparation
A549 NSCLC cells obtained from the Type Culture Collection of the Chinese Academy of Sciences (Beijing, China) were cultured in Dulbecco's Modified Eagle Medium with 10% fetal bovine serum (Thermo Fisher Scientific, USA) at the incubator with 37 C, 5% CO 2 , and 100% humidity. Full length TCF-4 (1809 bp) was cloned from cDNA of A549 cells and inserted into pEGFP-N1-FLAG (#60360, Addgene, USA). Partial 10th exon (1129e1164 bp) was deleted by mutagenesis polymerase chain reaction (PCR) based on the wild type TCF-4. The plasmids of wild type TCF-4 and TCF-4-D1129À1164 were transfected into A549 cells, respectively using the X-tremeGENE HP DNA Transfection Reagent (Roche Diagnostics, Basel, Switzerland) in accordance with the manufacturer's instructions. A549 cells were harvested after 72 h transfection for the next experiments.
Chromatin Immunoprecipitation Sequence
The chromatin immunoprecipitation (ChIP) assay was performed as described [14] . In brief, 10% whole cell lysates were saved as input after genomic DNA was broken into 200e500 bp by sonication. One microgram of immunoprecipitation (IP)-grade antibodies of FLAG or b-catenin were incubated with the rest of the lysate overnight, followed by 2 h protein-A beads incubation at 37 C for target protein pull down. The FLAG or b-catenineenriched DNA or input DNA were repaired to 3 0 -dA overhang and added the ligated adapter. The DNA library eliminated the unligated adapters, and the appropriate size for sequence was selected using an Illumina Hiseq 2000 platform. The raw sequence reads of input and IP were trimmed adapters and filter out low quality reads using Cutadapt (version1.9.1) and Trimmomatic (version 0.35) [15] and checked the quality of clean reads using Fastqc [16] . Then, clean reads were mapped to the human genome (assembly hg38) using the Bowtie 2 (version 2.2.6) algorithm [17] . The process of peak calling (P < 0.01) were performed by MACS 2 (version 2.1.1) [18] and analyzed the different binding domains based on false discovery rate (FDR) value less than 0.05 and annotated by DiffBind [19] . De novo motif were analyzed using the R language and MEME [20e22]. The peaks on certain genomic loci were visualized by Integrative Genomics Viewer. Gene ontology (GO) analysis was used to interpret the biological function of the genes associated with differential peaks [23] . TCF-4 and b-catenin sequencing data were deposited to sequence read archive (SRA) database assigned with the accession number PRJNA551776.
Real-time PCR
Total RNA of A549 cells were isolated using the TRIzol (Thermo Fisher Scientific). DNA templates taken from RNA reverse transcription was detected by the target gene transcription using the QuantStudio 3 system (Thermo Fisher Scientific). In accordance with the given instructions, 95 C for 30 s for initial denaturation, followed by 40 cycles at 95 C for 5 s, appropriate annealing temperatures of 10 s and 72 C, then 30 s were setup for PCR conditions. Ct values were harvested and calculated by using the deltaedelta method. The expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a quality control. All primers used in this study were listed in Supplementary Table 1 . 
Cell Proliferation CCK-8 Assay
Statistical Analysis
The experimental data were processed with SPSS 20 software. c 2 test was used to analyze the correlation between TCF-4 mutation and tumor malignancy. Student's t-test was used for comparison of the difference between wild type and mutant TCF-4 groups. P value less than 0.05 was considered as statistical significance.
Results
The Relationship Between TCF-4 Mutations and Cancer Progression in vivo
Initially, we investigated the mutation atlas of the coding region of TCF-4 in cancer patients through TCGA database mining. Except 13 fusion protein, 169 point mutations (1.6%) were found in total 32 types of cancer (10528 cases samples), and 59 were involved in b-cateninebinding domain, 30 were distributed in HMG box whereas the rest of 80 mutations were in other coding region. Furthermore, we analyzed the correlation between the location of TCF-4 mutations and tumor malignancy, and we found that the tumors with TCF-4 mutations at HMG box displayed a lower malignancy of tumor than the ones with the mutations at b-cateninebinding domain (c 2 ¼ 3.979, P ¼ 0.038) and other regions (c 2 ¼ 8.317, P ¼ 0.003) ( Figure 1A) . Moreover, the overall survival status was also compared among these three groups of TCF-4 mutations within b-cateninebinding domain, HMG box domain as well as other regions. We observed that both the patients of TCF-4 mutations within b-cateninebinding domain (P ¼ 0.011) and HMG box domain (P ¼ 0.009) displayed higher overall survival rate than the ones of TCF-4 mutations within other regions ( Figure 1B) . We also noticed that the hot spot mutation at HMG box focused on the key DNA-binding sites ("FMLYM" from 357 to 361 and "SAAINQILGRRW" from 377 to 388 at the 10th exon, although Translational Oncology Vol. 13, No. 1, 2020 The Impact of HMG Box Mutation of TCF-4 Su et al.
"AKYYELARKER" from 397 to 407 at the 11th exon) ( Figure 1C ). Taken together, our results determined that TCF-4 mutations within HMG box was supposed to be benefit for tumor suppression.
Genomic Binding Patterns of HMG Box Mutation of TCF-4
We observed that there are more lung cancer patients with mutations within "SAAINQILGRRW" than other two regions ("SAAINQILGRRW": 7 cases; "FMLYM": 3 cases; "AKYYELAR-KER": 2 cases). Consequently, we generated the ectopic plasmids of TCF-4 with wild type and "SAAINQILGRRW" deletion (TCF-4-D1129À1164 ) both combined with FLAG-tag. Sanger sequence validated the mutagenesis of TCF-4 ( Supplementary Figure 1) . A549 NSCLC cells were transfected to overexpress wild type or TCF-4 D1129À1164 ,respectively, and a pull-down assay was subsequently performed using FLAG-tag or b-catenin antibodies to conduct the deep sequencing for mapping genome-wide TCF-4 profiles in A549 NSCLC cells. Approximately, 82.23 M reads of TCF-4 and 80.37 M reads of b-catenin ChIP sequencing data were collected, respectively (Supplementary Table 2 ). We observed that the genomic occupancy of TCF-4 was remarkably dependent on these mutant binding sites. TCF-4 D1129À1164 substantially weakened the genomic enrichment compared with the wild type group (P ¼ 0.002) (Figure 2A ). TCF-4 D1129À1164 lost the occupancy at 19365 regions but gained additional 1724 peaks compared with wild type TCF-4 (log 2 FC > 1 or < -1, FDR<0.01) ( Figure 2B ). Nevertheless, 51.77% of total genomic binding regions of TCF-4 D1129À1164 were primarily concentrated on promoter regions, which was higher than 21.94% of wild type TCF-4 (P < 0.001). However, the overall enrichment of b-catenin on genome seemingly displayed no significant change responding to wild type TCF-4 or TCF-4 D1129À1164 , although b-catenin lost 4035 peaks but gained another 5287 peaks upon TCF-4 D1129À1164 compared with the wild type ( Supplementary  Figure 2A and B) . The examples of two different tendency of TCF-4 binding status such as KRT1, KRT14, LOR, MMP1 as well as H3F3C, MMP15 compared between wild type TCF-4 and TCF-4-D1129À1164 were illustrated ( Figure 2C) . Moreover, we observed that the TCF-4 D1129À1164 displayed a varying preferential DNA motif compared with the wild type TCF-4 ( Figure 2D ). Collectively, our ChIP-seq data determined a distinct pattern of TCF-4 binding at genome upon HMG box partial deletion.
The Tumor Repressive Effect of HMG Box Mutation of TCF-4 on NSCLC Cells
To further investigate the biological impact of differential genomic interaction derived from the TCF-4 D1129À1164 , GO analysis was used to analyze the function of genes associated with the differential occupancy of TCF-4 D1129À1164 . We observed that the function of angiogenesis, cell growth, cell morphogenesis, and multiple pathways including MAPK, PI3K-Akt, and Wnt were involved in the genes associated with the differential peaks from TCF-4 pull down compared between wild type TCF-4 and TCF-4 D1129À1164 (Figure 3A and B) . The transcription of associated genes such as KRT1, KRT14, and MMP1 were activated although H3F3C and MMP15 were inactivated upon TCF-4 D1129À1164 compared with wild type validated by quantitative polymerase chain reaction (qPCR) ( Figure 3C) , which was consistent with the data of ChIP-seq ( Figure 2C ). Finally, the ability of cell proliferation and invasion was explored to evaluate the overall efficacy of TCF-4 D1129À1164 in A549 cells by CCK-8 and transwell assay ( Figure 3D and E) . The presence of the compromising cell proliferation and invasion was observed in A549 cells with TCF-4 D1129À1164 compared with wild type, which was coincided with the TCGA data above in vivo.
Taken together, our results revealed that TCF-4 D1129À1164 affected its genomic binding status and could change the activation of multiple signaling pathways and induce the tumor repression in NSCLC cells.
Discussion
TCF-4 is broadly expressed in a variety of cell types, including lung, bladder, brain, fat, endometrium, ovary, and placenta [24] and functions in many cell lineageespecific functions, such as development of lymphocytes, neurogenesis, myogenesis, erythrogenesis, and melanogenesis [1, 25] . Of all the Wnt signaling pathway components, the TCF/LEF family works with b-catenin as the coactivators to initiate the transcription of Wnt targets. Previous studies have indicated that HMG box encoded by 10th and 11th exons exerted as a DNA-binding domain [9, 26] . More studies focused on the protein structure and function of TCF-4/catenin complex [27, 28] . However, it remained obscure how the binding activity between TCF-4 protein and target genes was regulated especially when HMG box mutation occurred.
The overactivation of Wnt signaling pathway is well acknowledged to promote cell growth and invasion, thereby strongly linking with carcinogenesis [5, 29, 30] . However, we noticed that the cancer patients with HMG box mutation of TCF-4 showed a characterization of compromising tumor malignancy and improving survival status compared with the wild type or mutations at other region of TCF-4 ( Figure 1A and B) . These results indicate that HMG box of TCF-4 may be a crucial part to limit cancer progression more than b-cateninebinding domain and other regions. It makes sense that the Wnt pathway even if activated cannot enhance the transcription of the downstream targets. However, if the HMG box is completely deleted, this pathway is supposed to break down, and the cells fall into the greater chaos. Considering about the pattern of TCF-4 mutation in lung cancer from TCGA database, we generated TCF-4 with HMG partial (SAAINQILGRRW) deletion containing most of the hot spot mutation in vivo. Consistently, the ChIP-seq data directly demonstrate that HMG box mutation decreases the occupancy of genomic DNA compared with wild type in our model (Figure 2A) .
Unexpectedly, a new preferential DNA motif recognized by TCF-4 D1129À1164 ( Figure 2D ) was observed compared with wild type 5 0 -CTTTGWWS-3 0 suggested by previous study [31] . We speculate that this deletion may cause a changed HMG box of TCF-4. The currently known TCF-4 structures (PDB No.: 1JPW and 2GL7, 1HSM) only displayed a patchy peptide associated with b-cateninebinding domain without HMG box and indicated little information on the protein structure between HMG box and interacted DNA. Given the new genomic regions bound by TCF-4 D1129À1164 compared with wild type from ChIP-seq data, although we cannot figure out the new protein structure based on this mutation, the TCF-4 gain of function is assumed and further studied. Previous study reported that the single nucleotide polymorphism (SNP) on TCF-4 enhanced the binding affinity with high mobility group box 1 (HMGB1) [32] , which implied a potential gain of function derived from mutation. Now, our results reveal that TCF-4 D1129À1164 produces a new recognition on the transcription of some genes such as KRT1, KRT14, LOR, and MMP1 (Figure 3AeC ), which is consistent with previous studies [7, 33] . Therefore, TCF-4 D1129À1164 is supposed to gain a novel function in cancer cells. The overall compromising effect of cell growth and invasion of A549 cells upon TCF-4 D1129À1164 are observed ( Figure 3D and E) .
In addition, the phenotype of b-catenin on genomic binding and transcription activity is not affected by TCF-4 ( Supplementary   Figure 2 ). This way of b-catenin is determined to be partially independent with TCF/LEF on genomic binding and transcriptional activation. The molecular mechanisms underlying b-catenineindependent Wnt signaling cascades and their implications for cell biology, development, and physiology was characterized previously [34] . However, it is hard to figure out the regulatory way of b-catenin in this study because our cell model is based on the ectopic TCF-4 overexpression without the endogenous TCF-4 deletion. We believe the targeted genomic fragments from b-catenin pull down is partially overlapped with endogenous TCF-4 in A549 cells.
Taken together, our results determine an important role of HMG box of TCF-4 in tumor suppression of NSCLC cancer. The HMG box of TCF-4 or the novel downstream genes gained by mutant TCF-4 are worthy of exploitation as the possible tumor treatment targets.
